CASE ON/4-32548A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1614

JOSEPH ALEXANDER LASKY

INTERNATIONAL APPLICATION NO: PCT/JB03/02794

FILED: 17 JUNE 2003

U.S. APPLICATION NO: 10/518,988 \

35 USC §371 DATE: 7 NOVEMBER 2006

FOR: 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-

PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE FOF

TREATING PULMONARY FIBROSIS

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Attorney for Applicant

Reg. No. 48,152

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7852

Date: 1/23/07

FORM PTO-1449 (REV. 7-85)

JAN 2 3 2007

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

() se several sheets if necessary)

ATTY. DOCKET NO. ON/4-32548A APPLICATION NO. 10/518,988 **APPLICANT** Joseph Alexander LASKY
FILING DATE NOVEMBER 7, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
АВ						
AC						
AD						
AE						
AF						
AG						
AH			***			
AI						
AJ						
AK						
AL						

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
AM	* WO 99/03854	01/28/99	WIPO				
AN							
AO							
AP							
AQ							

OTHER ROCHMENTS 4

		OTHER DOCUMENTS (Inclu	iding Author, Title, Date, Pertinent pages, Etc.)
	AR	American Thoracic Society, "Idiopathic Crit Care Med, Vol. 161, pp. 646-664 (Pulmonary Fibrosis: Diagnosis and Treatment, <i>Am J Respir</i> (2000).
-	AS	* Beers, "Idiopathic Bronchiolitis Oblite Diagnosis and Therapy, Merck Reseat	erans with Organizing Pneumonia", <i>The Merck Manual of</i> rch Laboratories, Whitehouse Station, NJ, pp. 638-639 (1999).
•	АТ	* Boecklin et al., "Anti-fibrogenic Effect Fibrosis in Chronic Myeloid Leukemia"	t of the Tyrosine Kinase Inhibitor STI-571 on Bone Marrow ', <i>Blood</i> , Vol. 96, No. 11, Pt. 1, p. 734a (2000).
EXAMIN	ER	/Craig Ricci/	DATE CONSIDERED 05/27/2008

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in *EXAMINER: conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

e several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. ON/4-32548A APPLICATION NO. 10/518,988 APPLICANT Joseph Alexander LASKY FILING DATE NOVEMBER 7, 2006

Group

EXAMINER

THER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

TRADEAN				
DA	Bonner et al., "Induction of PDGF Receptor-alp Fibrogenesis In Vivo", <i>Am J Physiol</i> , Vol. 274,	ha in Rat Myofibroblasts During Pulmonary Suppl. 1, Pt. 1, pp. L72-L80 (1998).		
DB	Driscoll et al., "Stimulation of Rat Alveolar Maci Model of Lung Injury and Fibrosis", <i>Toxicol App</i> (Abstract).	rophage Fibronectin Release in a Cadmium Chloride of Pharmacol, Vol. 116, No. 1, pp. 30-37 (1992)		
DC	Fauci et al., Harrison's Principles of Internal Me	edicine, Vol. 2, 14 th Edition, McGraw-Hill (1997).		
DD	Gross and Humingholes "Idionathis D. L			
DE	Harrison's Online, "Individual Forms of ILD", Cr	napter 259: Interstitial Lung Diseases, p. 14.		
DF	John et al., "Increased Production of Matrix Me Regulation by Interleukin-10 in Patients with Ac Vol. 28, No. 1, pp. 55-68 (2002) (abstract).	talloproteinase-2 in Alveolar Macrophages and cute Pulmonary Sarcoidosis", Exp Lung Res,		
DG	Katzenstein and Meyers, "Idiopathic Pulmonary Classification", Am J Respir Crit Care Med, Vol	Fibrosis. Clinical Relevance of Pathologic . 157, No. 4, pp. 1301-1315 (1998).		
DH	King, Jr., "Interstitial Lung Disease, Harrison's Online, Chapter 259, p. 1.			
DI	Lasky and Brody, "Interstitial Fibrosis and Growth Factors", <i>Environ Health Perspect</i> , Vol. 108 No. 8, Suppl. 4, pp. 751-762 (2000).			
DJ	Lindroos, Wang, Rice and Bonner, "Regulation of PDGRF-α in Rat Pulmonary Myofibroblas Staurosporine", <i>Am J Physiol Lung Cell Mol Physiol</i> , Vol. 280, No. 2, pp. L354-L352 (2001)			
DK	DK Marshall, McAnulty and Laurent, "The Pathogenesis of Pulmonary Fibrosis: Is There a Fibrosis Gene?", Int J Biochem Cell Biol, Vol. 29, No. 1, pp. 107-120 (1997). DL Nagai, Nagao, Hoshino and Hamada, "Heterogeneity of Pulmonary Fibrosis: Interstitial Pneumonias and Sarcoidosis", Curr Opin Pulm Med, Vol. 7, No. 5, pp. 262-271 (2001). DM Paine, III and Ward, "Cell Adhesion Molecules and Pulmonary Fibrosis", Am J Med, Vol. 107, No. 3, pp. 268-279 (1999). DN Reynolds, "Interstitial Lung Diseases", Chapter 259, pp. 1460-1465.			
DL				
DM				
DN				
DO	Rice, Moomaw, Morgan and Bonner, "Specific Inhibitors of Platelet-derived Growth Factor or			
DP	Romanska et al., "Up-regulation of Inducible Nitric Oxide Synthase in Fibroblasts Parallels the Onset and Progression of Fibrosis in an Experimental Model of Post-transplant Obliterative Airway Disease", <i>J Pathol</i> , Vol. 191, No. 1, pp. 71-77 (2000).			
DQ	Yoursem "Pulmonary Anical Cones A Distinction	but Poorly Recognized Lesion in Pulmonary		
EXAMINER		ONSIDERED 05/27/2008		

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.